Antibody Drug Conjugates
Antibody Drug Conjugates
Characterize and optimize ADCs with specialized cytotoxicity assays, payload activity detection, and comprehensive target engagement analysis tools.
Precision Tools for ADC Development
Antibody drug conjugates represent one of the most promising modalities in targeted therapeutics, combining antibody specificity with potent cytotoxic payloads. Enzo Life Sciences provides specialized tools for ADC development — from cell-based cytotoxicity assays measuring payload delivery and activity to comprehensive binding and characterization platforms for evaluating conjugation efficiency, stability, and target selectivity.
Cytotoxicity & Payload Activity
Quantitative cell viability and cytotoxicity assays for measuring ADC-mediated cell killing. Our platforms distinguish between payload-dependent cytotoxicity and non-specific toxicity, supporting DAR optimization and linker stability assessment.
Target Binding Analysis
Antibody binding assays and receptor quantification tools for evaluating ADC target engagement. ELISA-based antigen binding, receptor density measurement, and internalization assays for optimizing ADC targeting efficiency.
Mechanism of Cell Death
Detailed cell death mechanism profiling for ADC-treated cells using apoptosis, mitotic arrest, and DNA damage markers. APOPCYTO and CYTO-ID platforms enable mechanistic characterization of ADC cytotoxic activity for regulatory documentation.
Immune Effector Functions
Assays for measuring antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and Fc receptor binding. Characterize the immune effector contribution to ADC therapeutic activity alongside payload-mediated killing.
Antibody Drug Conjugates — By the Numbers
Accelerate Your ADC Program
Explore our curated product selection or contact our scientific support team for personalized recommendations.